AccuRna

Tokyo, Japan· Est. 2015

AccuRna develops novel drug delivery platforms for nucleic acid therapeutics including siRNA, ASO, miRNA, and mRNA to treat refractory diseases.

accurna.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Estimated funding: $4.2M

AI Company Overview

AccuRna develops novel drug delivery platforms for nucleic acid therapeutics including siRNA, ASO, miRNA, and mRNA to treat refractory diseases.

OncologyInfectious Disease

Technology Platform

Novel drug delivery systems (DDS) for nucleic acid therapeutics capable of delivering both short-chain (ASO, siRNA, miRNA) and long-chain (mRNA) RNA modalities, with potential application to CRISPR-Cas systems.

Opportunities

Growing demand for nucleic acid therapeutics post-COVID-19 creates significant partnership opportunities for delivery platform companies; versatility across RNA modalities could attract multiple pharmaceutical collaborators.

Risk Factors

As a preclinical platform company with undisclosed validation data, technical risks around delivery efficacy and safety remain unproven; intense competition in RNA delivery from better-funded companies presents commercial challenges.

Competitive Landscape

Competes with established RNA delivery companies like Alnylam (GalNAc-conjugates), Moderna/BioNTech (LNPs), and Arrowhead Pharmaceuticals; differentiation through platform versatility across multiple nucleic acid types rather than modality-specific solutions.

More companies in Japan →